Market Closed -
Swiss Exchange
11:31:13 2024-05-23 am EDT
|
5-day change
|
1st Jan Change
|
2.208
CHF
|
-2.13%
|
|
-5.88%
|
+4.45%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
3,929
|
4,248
|
3,298
|
2,383
|
376.8
|
395.2
|
-
|
-
|
Enterprise Value (EV)
1 |
3,769
|
3,828
|
4,290
|
3,367
|
376.8
|
1,579
|
1,727
|
2,343
|
P/E ratio
|
-7.96
x
|
-8.21
x
|
-4.94
x
|
-2.87
x
|
-1.27
x
|
-1.48
x
|
-2.25
x
|
-4.13
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
164
x
|
59
x
|
94.2
x
|
24.6
x
|
2.48
x
|
2.92
x
|
1.52
x
|
0.87
x
|
EV / Revenue
|
157
x
|
53.2
x
|
123
x
|
34.7
x
|
2.48
x
|
11.7
x
|
6.62
x
|
5.14
x
|
EV / EBITDA
|
-8.16
x
|
-9.79
x
|
-7.21
x
|
-4.57
x
|
-0.78
x
|
-4.25
x
|
-6.55
x
|
-43.3
x
|
EV / FCF
|
-7.02
x
|
-10.2
x
|
-6.87
x
|
-3.84
x
|
-
|
-2.88
x
|
-4.56
x
|
-
|
FCF Yield
|
-14.2%
|
-9.77%
|
-14.5%
|
-26%
|
-
|
-34.8%
|
-21.9%
|
-
|
Price to Book
|
22.8
x
|
6.24
x
|
31.7
x
|
-3.61
x
|
-
|
-0.49
x
|
-0.41
x
|
-0.22
x
|
Nbr of stocks (in thousands)
|
131,235
|
166,466
|
176,955
|
177,543
|
178,261
|
178,967
|
-
|
-
|
Reference price
2 |
29.94
|
25.52
|
18.64
|
13.42
|
2.114
|
2.208
|
2.208
|
2.208
|
Announcement Date
|
2/6/20
|
2/4/21
|
2/8/22
|
2/7/23
|
5/21/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
24
|
72
|
35
|
97
|
152
|
135.3
|
260.7
|
455.5
|
EBITDA
1 |
-462
|
-391
|
-595
|
-737.2
|
-482
|
-371.3
|
-263.4
|
-54.15
|
EBIT
1 |
-482
|
-411
|
-613
|
-757
|
-501
|
-388.9
|
-331.4
|
-141.9
|
Operating Margin
|
-2,008.33%
|
-570.83%
|
-1,751.43%
|
-780.41%
|
-329.61%
|
-287.38%
|
-127.12%
|
-31.15%
|
Earnings before Tax (EBT)
1 |
-485
|
-449
|
-634.8
|
-820.1
|
-294
|
-406.7
|
-358.1
|
-166.6
|
Net income
1 |
-494
|
-445
|
-635
|
-828
|
-298
|
-406.7
|
-348.9
|
-160.8
|
Net margin
|
-2,058.33%
|
-618.06%
|
-1,814.29%
|
-853.61%
|
-196.05%
|
-300.51%
|
-133.84%
|
-35.3%
|
EPS
2 |
-3.760
|
-3.110
|
-3.770
|
-4.670
|
-1.670
|
-1.490
|
-0.9818
|
-0.5349
|
Free Cash Flow
1 |
-536.8
|
-373.9
|
-624
|
-875.7
|
-
|
-548.9
|
-378.8
|
-
|
FCF margin
|
-2,236.86%
|
-519.35%
|
-1,782.86%
|
-902.81%
|
-
|
-405.56%
|
-145.27%
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
2/6/20
|
2/4/21
|
2/8/22
|
2/7/23
|
5/21/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 S1
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
---|
Net sales
1 |
13
|
5
|
5
|
17
|
21
|
54
|
21
|
30
|
80
|
22
|
10.06
|
112.3
|
13.35
|
21.09
|
52.45
|
EBITDA
|
-
|
-224
|
-187.8
|
-207
|
-189
|
-174.3
|
-193
|
-173
|
-37
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-234
|
-228
|
-193
|
-212
|
-193
|
-180
|
-198
|
-177
|
231
|
-115
|
30.94
|
-16.49
|
-121.5
|
-124.1
|
-80.4
|
Operating Margin
|
-1,800%
|
-4,560%
|
-3,860%
|
-1,247.06%
|
-919.05%
|
-333.33%
|
-942.86%
|
-590%
|
288.75%
|
-522.73%
|
307.63%
|
-14.68%
|
-909.78%
|
-588.48%
|
-153.29%
|
Earnings before Tax (EBT)
|
-
|
-253
|
-196
|
-222
|
-216
|
-190.3
|
-212
|
-192
|
225
|
-116
|
-
|
-
|
-
|
-
|
-
|
Net income
|
-223
|
-252
|
-198
|
-222
|
-216
|
-193
|
-212
|
-193
|
224
|
-117
|
-
|
-
|
-
|
-
|
-
|
Net margin
|
-1,715.38%
|
-5,040%
|
-3,960%
|
-1,305.88%
|
-1,028.57%
|
-357.41%
|
-1,009.52%
|
-643.33%
|
280%
|
-531.82%
|
-
|
-
|
-
|
-
|
-
|
EPS
2 |
-1.340
|
-1.460
|
-1.120
|
-1.250
|
-1.220
|
-1.090
|
-1.190
|
-1.080
|
0.9600
|
-0.6500
|
0.1300
|
-0.1000
|
-0.4100
|
-0.3000
|
-0.2000
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
7/27/21
|
2/8/22
|
4/26/22
|
7/26/22
|
10/25/22
|
2/7/23
|
4/25/23
|
7/25/23
|
10/24/23
|
5/21/24
|
5/21/24
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
991
|
984
|
-
|
1,184
|
1,331
|
1,948
|
Net Cash position
1 |
160
|
421
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-1.666
x
|
-1.335
x
|
-
|
-3.188
x
|
-5.055
x
|
-35.97
x
|
Free Cash Flow
1 |
-537
|
-374
|
-624
|
-876
|
-
|
-549
|
-379
|
-
|
ROE (net income / shareholders' equity)
|
-118%
|
-103%
|
-167%
|
-
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-32.1%
|
-39.4%
|
-65.5%
|
-
|
-58.4%
|
-34.5%
|
-19.4%
|
Assets
1 |
-
|
1,385
|
1,611
|
1,264
|
-
|
696.3
|
1,010
|
830.8
|
Book Value Per Share
2 |
1.310
|
4.090
|
0.5900
|
-3.720
|
-
|
-4.540
|
-5.400
|
-9.950
|
Cash Flow per Share
2 |
-3.520
|
-2.550
|
-3.500
|
-4.840
|
-
|
-3.170
|
-1.350
|
-0.4700
|
Capex
1 |
18.8
|
9.27
|
25.5
|
16.6
|
-
|
15.9
|
22.8
|
64.5
|
Capex / Sales
|
78.34%
|
12.87%
|
72.93%
|
17.13%
|
-
|
11.75%
|
8.73%
|
14.16%
|
Announcement Date
|
2/6/20
|
2/4/21
|
2/8/22
|
2/7/23
|
5/21/24
|
-
|
-
|
-
|
Mean consensus UNDERPERFORM Last Close Price
2.208
CHF Average target price
1.692
CHF Spread / Average Target -23.35% Consensus |
1st Jan change
|
Capi.
|
---|
| +4.45% | 442M | | +10.79% | 115B | | +11.65% | 106B | | -6.20% | 24.69B | | -2.33% | 21.97B | | -6.03% | 19.27B | | -13.41% | 17.56B | | -40.50% | 17.32B | | +6.64% | 14.03B | | +31.84% | 12.13B |
Bio Therapeutic Drugs
|